论文部分内容阅读
目的:比较门冬氨酸阿奇霉素与红霉素治疗儿童支原体肺炎的临床疗效和不良反应。方法:将54例支原体肺炎患儿随机分为两组,34例采用门冬氨酸阿奇霉素10 mg.kg-1.d-1静脉滴注,用药3 d停4 d(>5岁者停3 d),再用3 d;20例静脉滴注红霉素30 mg.kg-1.d-1,疗程10 d。治疗结束后根据疗效评定标准比较两组疗效和不良反应。结果:门冬氨酸阿奇霉素和红霉素治疗儿童支原体肺炎均有较好的疗效,但门冬氨酸阿奇霉素组临床症状恢复时间、临床痊愈率均优于红霉素(P<0.05),而不良反应发生率低于红霉素(P<0.05)。结论:静脉滴注门冬氨酸阿奇霉素治疗儿童支原体肺炎疗效确切,治疗时间短,不良反应少,患儿依从性好,值得在临床上推广使用。
Objective: To compare the clinical efficacy and side effects of azithromycin aspartate and erythromycin in children with mycoplasma pneumonia. Methods: 54 cases of children with mycoplasma pneumonia were randomly divided into two groups, 34 cases of intravenous infusion of aspartame azithromycin 10 mg.kg-1.d-1, 3 d dosing stopped 4 days (> 5 years old stopped 3 d), then 3 d; 20 cases of intravenous infusion of erythromycin 30 mg.kg-1.d-1, treatment of 10 d. After treatment, the efficacy and adverse reactions of the two groups were compared according to the evaluation standard of curative effect. Results: Both azithromycin aspartate and erythromycin had better curative effect on mycoplasma pneumonia in children, while recovery time and clinical cure rate of azithromycin aspartate group were better than that of erythromycin (P <0.05). The incidence of adverse reactions was lower than that of erythromycin (P <0.05). Conclusion: Intravenous azithromycin aspartate treatment of children with mycoplasma pneumonia is effective, short treatment time, fewer adverse reactions, good compliance in children, it is worth promoting in clinical use.